NNVC — NanoViricides, Share Price
Last trade - 00:00- $18.98m
- $17.85m
- 20
- 21
- 38
- 14
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.65 | ||
| Price to Tang. Book | 2.77 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -114.57% | ||
| Return on Equity | -94.03% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.
Directors
- Anil Diwan CHM (63)
- Meeta Vyas CFO (63)
- Stanley Glick IND (85)
- Makarand Jawadekar IND (70)
- Theodore Rokita IND (51)
- Brian Zucker IND (59)
- Last Annual
- June 30th, 2025
- Last Interim
- September 30th, 2025
- Incorporated
- May 30th, 2023
- Public Since
- August 12th, 2004
- No. of Shareholders
- 143
- No. of Employees
- 7
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 21,568,429
- Address
- 1 Controls Drive, SHELTON, 06484
- Web
- https://www.nanoviricides.com/
- Phone
- +1 2039376137
- Auditors
- EisnerAmper LLP
Latest News for NNVC
Upcoming Events for NNVC
Q2 2026 NanoViricides Inc Earnings Release
Similar to NNVC
Actinium Pharmaceuticals
NYSE MKT
Aeon Biopharma
NYSE MKT
AIM ImmunoTech
NYSE MKT
Apimeds Pharmaceuticals US
NYSE MKT
Armata Pharmaceuticals
NYSE MKT
FAQ
As of Today at 12:11 UTC, shares in NanoViricides, are trading at $0.88. This share price information is delayed by 15 minutes.
Shares in NanoViricides, last closed at $0.88 and the price had moved by -28.46% over the past 365 days. In terms of relative price strength the NanoViricides, share price has underperformed the S&P500 Index by -37.81% over the past year.
The overall consensus recommendation for NanoViricides, is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreNanoViricides, does not currently pay a dividend.
NanoViricides, does not currently pay a dividend.
NanoViricides, does not currently pay a dividend.
To buy shares in NanoViricides, you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.88, shares in NanoViricides, had a market capitalisation of $18.98m.
Here are the trading details for NanoViricides,:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: NNVC
Based on an overall assessment of its quality, value and momentum NanoViricides, is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in NanoViricides, is $6.33. That is 619.32% above the last closing price of $0.88.
Analysts covering NanoViricides, currently have a consensus Earnings Per Share (EPS) forecast of -$0.47 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NanoViricides,. Over the past six months, its share price has underperformed the S&P500 Index by -48.79%.
As of the last closing price of $0.88, shares in NanoViricides, were trading -37.18% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The NanoViricides, PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.88.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
NanoViricides,'s management team is headed by:
- Anil Diwan - CHM
- Meeta Vyas - CFO
- Stanley Glick - IND
- Makarand Jawadekar - IND
- Theodore Rokita - IND
- Brian Zucker - IND